设为首页 |  加入收藏 |  联系我们

如:神经外科 骨科 手外科 眼科 神经内科……

神经生长因子对重型颅脑损伤患者的治疗效果及血清MMP-2、NSE 影响研究

发布日期:2017-02-10 点击次数:1139 字体显示:【大】  【中】  【小】

神经生长因子对重型颅脑损伤患者的治疗效果及血清MMP-2、NSE 影响研究

【作者】 缪一艇,童凌云,王勇,马为众,张华暹,金鹏程

【Author】 MIAO Yi-ting,TONG Ling-yun,WANG Yong,et al.

【作者单位】 温州市人民医院神经外科

 

【摘要】 目的 探究神经生长因子对重型颅脑损伤患者的治疗效果及血清基质金属蛋白酶-2(MMP-2)、血清神经元特异性烯醇化酶(NSE)水平影响研究,以为重型颅脑损伤患者的治疗提供参考。方法 分析2014 年6 月—2015 年12 月91 例在温州市人民医院接受治疗的重症颅脑损伤患者的临床资料,对照组(44 例)给予常规对症治疗,观察组(47 例)在常规治疗基础上增加鼠神经生长因子进行治疗。比较2 组患者治疗前后血清MMP-2、NSE水平、GCS 评分及不良发应发生率的差异。结果 观察组患者治疗14 d 后血清中MMP-2、NSE 水平明显低于治疗前水平,观察组治疗14 d 后MMP-2 明显高于对照组,观察组治疗14 d 后NSE 水平低于对照组,差异均具有统计学意义(P < 0. 05);2 组患者治疗14 d 后GCS 评分明显高于治疗前,观察组患者治疗14 d 后GCS 评分显著高于对照组,差异均具有统计学意义(P < 0. 05);治疗2 周后,观察组患者中出现恶心、呕吐3 例,头晕2 例,下肢疼痛2 例,不良反应率14. 89%,对照组中恶心、呕吐2 例,头晕1 例,心率失常1 例,不良反应率9. 09%,2 组患者不良反应发生率比较,差异不具有统计学意义(χ2 = 0. 720,P = 0. 396)。结论 神经生长因子可明显降低血清中MMP-2、NSE 水平,有助于患者神经功能的恢复,安全性较好。

【Abstract】Objective To investigate the curative effect of nerve growth factor on severe craniocerebral injury and its influence on the levels of matrix metalloproteinase-2(MMP-2) and neuron-specific enolase(NSE),to provide reference for the treatment of patients with severe craniocerebral injury. Methods The clinical data of 91 cases of severe craniocerebral injury in our hospital between June,2014 and December,2015 was reviewed. The control group(44 cases) received conventional symptomatic treatment,while the observation group(47 cases) received additional nerve growth factor treatment on the basis of conventional treatment. The levels of serum NSE and MMP-2,GCS score and the incidence of adverse incidence before and after the treatment were compared between the two groups. Results The serum level of MMP-2 and NSE at 14 d after the treatment in observation group was significantly lower than that before the treatment,the level of MMP-2 at d 14 after the treatment in the observation group was obviously higher than that in the control group,while the level of NSE at 14 d after the treatment in the observation group was lower than that in the control group,the difference was all statistically significant(P < 0. 05);GCS score of 14 days after treatment in Two groups was significantly higher than before treatment,GCS score at 14 d after the treatment in the observation group was significantly greater than that in the control group,the difference was statistically significant(P < 0. 05);After two weeks of treatment,the incidence of adverse reaction in the observation group was 14. 89% (nausea and vomiting in 3 cases,dizziness in 2 cases,and lower extremity pain in 2 cases) and in the control group was 9. 09% (nausea and vomiting in 2 cases,dizziness in 1 cases,and arrhythmia in 1 cases),there were no statistically significant difference(χ2 = 0. 720,P = 0. 396). Conclusion The nerve growth factor can obviously reduce the serum level of MMP-2 and NSE,and contribute to the recovery of neural function with a good security.

【关键词】 神经生长因子;颅脑损伤;基质金属蛋白酶-2;血清神经元特异性烯醇化酶

【Keywords】Nerve growth factor;Craniocerebral injury;Matrix metalloproteinase-2;Neuron-specific enolase

DOI: 10.16766 /j. cnki.issn.1674-4152.2016.12.021